Search

Your search keyword '"Žáčková D"' showing total 2 results
Start Over Author "Žáčková D" Journal leukemia
2 results on '"Žáčková D"'

1. Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.

Author

Žáčková D, Semerád L, Faber E, Klamová H, Stejskal L, Bělohlávková P, Karas M, Cmunt E, Černá O, Procházková J, Čičátková P, Kvetková A, Horňák T, Skoumalová I, Srbová D, Šálek C, Buffa D, Voglová J, Jurček T, Folta A, Ježíšková I, Žižková H, Machová Poláková K, Papajík T, Žák P, Jindra P, Svobodník A, Štěpánová R, and Mayer J

Subjects
Humans, Tyrosine Kinase Inhibitors, Czech Republic, Chronic Disease, Protein Kinase Inhibitors therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myeloid
Published
2024
Full Text
View/download PDF

2. Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI.

Author

Richter J, Lübking A, Söderlund S, Lotfi K, Markevärn B, Själander A, Stenke L, Deneberg S, Ahlstrand E, Myhr-Eriksson K, Panayiotidis P, Gedde-Dahl T, Žáčková D, Mayer J, Olsson-Strömberg U, Mahon FX, Saussele S, Hjorth-Hansen H, and Koskenvesa P

Subjects
Europe epidemiology, Fusion Proteins, bcr-abl genetics, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology, Neoplasm Recurrence, Local chemically induced, Neoplasm Recurrence, Local epidemiology, Prognosis, Remission Induction, Time Factors, Clinical Trials as Topic methods, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Neoplasm Recurrence, Local diagnosis, Protein Kinase Inhibitors adverse effects, Withholding Treatment statistics & numerical data
Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results